MannKind Welcomes New Leadership
In an exciting development for MannKind Corporation, the company is enhancing its executive leadership team with the addition of Dominic Marasco, RPh, who will serve as the President of the Endocrine Business Unit, effective immediately.
Dominic Marasco Joins MannKind
Marasco's arrival is an important milestone for MannKind, a company dedicated to creating innovative inhaled therapies for patients with serious endocrine conditions. His extensive experience in the biopharma industry, especially in commercial strategy, is expected to drive the company's efforts forward.
Leadership and Experience
Reporting directly to CEO Michael Castagna, PharmD, Marasco brings over 25 years of experience in the biopharmaceutical sector. He previously served as Executive President and Chief Commercial Officer at Envision Pharma Group, where he spearheaded advancements in technology and artificial intelligence.
Before that role, Marasco was the Chief Commercial Officer at BioAgilytix Labs, Inc., showcasing his capability to lead commercial operations effectively. His career also includes significant positions at Syneos Health and Amgen, where he played key roles in sales and global commercial strategies.
Future of MannKind’s Endocrine Business
With Marasco's expertise, MannKind is looking to enhance its operational excellence and accelerate growth in the recently revitalized Endocrine Business Unit. CEO Castagna expressed optimism, stating that Marasco's leadership will be transformational.
A Vision for Patients
Marasco himself shares this vision, as he expressed excitement about the potential of Afrezza, a unique inhalation therapy for diabetes management. He aims to collaborate with the team to broaden what is achievable in patient care, stating, "The energy behind Afrezza and the momentum of MannKind's pipeline is inspiring. I am eager to contribute to an innovative team dedicated to advancing endocrine health on a global scale."
About MannKind Corporation
MannKind Corporation focuses on developing and commercializing advanced inhaled therapeutic products. With a commitment to addressing pressing medical needs in endocrine and orphan lung diseases, the company utilizes innovative dry-powder formulations along with sophisticated inhalation devices.
The mission is to empower individuals with better health management solutions while alleviating the burden of chronic conditions like diabetes and pulmonary illnesses.
Our Commitment to Innovation
With a dedicated team, MannKind strives to push the boundaries of medical innovation, ensuring that patients can regain control over their health and improve their quality of life. The company's unique approach aims for rapid and convenient medicine delivery directly to the lungs.
Contact Information
If you wish to learn more about MannKind and its innovative products, please reach out to:
MannKind Contacts: Media Relations Christie Iacangelo (818) 292-3500 Email: media@mnkd.com Investor Relations Ana Kapor (818) 661-5000 Email: ir@mnkd.com
Frequently Asked Questions
Who is the new President of MannKind’s Endocrine Business Unit?
Dominic Marasco, RPh, has been appointed as the new President of the Endocrine Business Unit at MannKind Corporation.
What is MannKind Corporation focused on?
MannKind Corporation specializes in the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases.
What prior experience does Dominic Marasco have?
Marasco has over 25 years of experience in the biopharmaceutical industry, having held significant positions at companies such as Envision Pharma and BioAgilytix Labs.
What is the significance of Afrezza for MannKind?
Afrezza is MannKind’s innovative inhalation therapy for diabetes management, providing the company with growth potential in the market.
How does MannKind deliver its therapeutic products?
MannKind utilizes advanced dry-powder formulations and inhalation devices to ensure effective and rapid delivery of medications to patients.
